NextGen Bio
Filter News
Found 7,314 articles
-
FonesLife offers the 7,000-plex SomaScan® Platform as Japan’s first SomaLogic™ Certified Site
12/19/2022
SomaLogic, Inc., a leader in proteomic technology, announced that Tokyo-based FonesLife Corporation, will be the first SomaLogic™ Certified Site in Japan.
-
Xilis Announces Formation of its Scientific Advisory Board
12/15/2022
Xilis today announced the addition of four members to its newly formed Scientific Advisory Board (SAB).
-
Metagenomi Announces Publication of Data in Nature Communications Describing Novel, Ultra-Small Nucleases for Gene Editing
12/15/2022
Metagenomi Announces Publication of Data in Nature Communications Describing Novel, Ultra-Small Nucleases for Gene Editing.
-
Umoja Biopharma Appoints Dieter Weinand as the Chair of its Board of Directors
12/14/2022
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid and hematologic malignancies, announced the appointment of Dieter Weinand to its Board of Directors where he will take on the role of Chair, effective November 17, 2022.
-
Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting
12/11/2022
Graphite Bio, Inc. presented preclinical results supporting the use of a single-cell RNA sequencing method to assess gene correction outcomes in patients treated with nulabeglogene autogedtemcel, an investigational gene-edited therapy for sickle cell disease.
-
AltruBio Presents New Positive Data from its Completed Phase 1b Study Evaluating ALTB-168 in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022
12/10/2022
AltruBio Inc. announced the presentation of new data from its completed Phase 1b clinical trial evaluating ALTB-168 in patients with steroid-refractory or treatment-refractory acute graft-versus-host-disease at the 64th American Society of Hematology Annual Meeting, taking place December 10-13, 2022 in New Orleans, La.
-
Scorpion Therapeutics Presents Preclinical Data for Potential Best-in-Class PI3Kα Inhibitor at San Antonio Breast Cancer Symposium
12/8/2022
Scorpion Therapeutics Presents Preclinical Data for Potential Best-in-Class PI3K α Inhibitor at San Antonio Breast Cancer Symposium.
-
Crown Aesthetics Announces Revolutionary Study Proving Efficacy of Patented Xycrobe® Technology
11/22/2022
Crown Aesthetics, a Crown Laboratories, Inc. company, maintains its position at the forefront of skincare innovation with the unveiling of a new study in the Journal of Cosmetic Dermatology showcasing the efficacy of its patented Xycrobe® technology, formulated to address the often overlooked skin biome.
-
Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration to Bring Off-the-Shelf Therapies to Patients with Hematological Malignancies
11/21/2022
Umoja Biopharma, Inc. and IASO Biotherapeutics announced today that they have entered into a research agreement to evaluate Umoja's iCIL platform with IASO's best-in-class CARs,
-
Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference
11/21/2022
Graphite Bio, Inc. today announced that members of the management team will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Thursday, Dec. 1, 2022, at 11:45 a.m. ET.
-
In the acquisition, announced Wednesday, Kriya picks up two gene therapy programs focused on epilepsy and trigeminal neuralgia. Financial terms of the deal were not disclosed.
-
Kyverna Therapeutics Announces FDA Clearance of IND for KYV-101, a Novel Fully Human CD19 CAR T-Cell Therapy to Treat Lupus Nephritis
11/11/2022
Kyverna Therapeutics today announced the clearance of its first Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial of KYV-101, a novel therapy for the treatment of lupus nephritis.
-
Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting
11/10/2022
Werewolf Therapeutics, Inc. today announced that it will present preclinical data on mWTX-330, a mouse surrogate of its interleukin-12 (“IL-12”) INDUKINETM product candidate, WTX-330, at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) being held November 8-12, 2022, in Boston, and virtually.
-
SomaLogic Teams with Molecular Genomics to Bring the 7,000-Plex SomaScan® Platform to Asia
11/8/2022
SomaLogic, Inc., a leader in proteomics technology, announced that Singapore-based Molecular Genomics, a Genomax Technologies company, will be the first site in Asia to offer the 7,000-plex SomaScan® Assay and provide SomaScan data to their customers.
-
AltruBio to Present at Stifel 2022 Healthcare Conference
11/8/2022
AltruBio Inc. announced that AltruBio President and Chief Executive Officer Judy Chou, Ph.D., and Chief Financial Officer Jeroen Grasman will present a corporate overview at the Stifel 2022 Healthcare Conference taking place November 15-16, 2022 in New York, NY.
-
Korro Bio Expands Leadership Team with Key Appointments
11/8/2022
Korro Bio, Inc today announced the appointment of Venkat Krishnamurthy, Ph.D., as Senior Vice President, Head of Platform and Stephanie Engels as Senior Vice President, Head of People and Culture.
-
Scorpion Therapeutics Announces Formation of World-Class Clinical Scientific Advisory Board
11/7/2022
Scorpion Therapeutics, Inc., a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, announced the formation of its Clinical Scientific Advisory Board.
-
Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research
11/7/2022
Cerveau Technologies, Inc. announced a license agreement with LEXEO Therapeutics, Inc., which will enable LEXEO to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography scans to assess the status and progression of neurofibrillary tangles in the brain.
-
AltruBio to Present New Phase 1b Data Evaluating Neihulizumab (ALTB-168) in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022
11/3/2022
AltruBio Inc. announced the poster presentation of new data from its Phase 1b clinical trial evaluating neihulizumab in patients with steroid-refractory or treatment-refractory acute graft-versus-host-disease at the 64th American Society of Hematology Annual Meeting, taking place December 10-13, 2022 in New Orleans, La.
-
Scorpion Therapeutics is on a mission to create a world where many more cancer patients can benefit from precision therapies. Earlier this year, it struck a $75 million alliance with AstraZeneca.